Table 2.
Frequency of main adverse effects reported by the workers after the first and the second dose of the BNT162b2 anti-SARS-CoV-2 vaccine.
| Adverse Effect Reported | Vaccination Dose | Workers with the Adverse Effects% (N) * | Workers with the Adverse Effects in the COVID-19 Group% (N) * | Workers with the Adverse Effects in the Non-COVID-19 Group % (N) * |
p-Value |
|---|---|---|---|---|---|
| Redness in the injection site | 1st | 25.4 (17) | 33.3 (9) | 20.0 (8) | 0.219 |
| 2nd | 23.9 (16) | 25.9 (7) | 22.5 (9) | 0.747 | |
| Pain in the injection site | 1st | 73.6 (53) | 80.0 (24) | 69. 0 (29) | 0.299 |
| 2nd | 68.1 (49) | 73.3 (22) | 64.3 (27) | 0.417 | |
| Fever | 1st | 7.5 (5) | 7.1 (2) | 7.7 (3) | 0.933 |
| 2nd | 17.9 (12) | 17.9 (5) | 17.9 (7) | 0.992 | |
| Asthenia | 1st | 37.5 (27) | 51.7 (15) | 27.9 (12) | 0.041 |
| 2nd | 48.6 (35) | 48.3 (14) | 48.8 (21) | 0.963 | |
| Myalgia | 1st | 23.1 (15) | 29.6 (8) | 18.4 (7) | 0.291 |
| 2nd | 32.3 (21) | 37.0 (10) | 28.9 (11) | 0.492 | |
| Arthralgia * | 1st | 22.1 (15) | 35.7 (10) | 12.5 (5) | 0.023 |
| 2nd | 32.4 (22) | 42.9 (10) | 25.0 (10) | 0.121 | |
| Headache/migraine | 1st | 25.0 (17) | 35.7 (10) | 17.5 (7) | 0.088 |
| 2nd | 30.9 (21) | 39.3 (11) | 25.0 (10) | 0.210 | |
| Chills | 1st | 18.8 (13) | 20.0 (6) | 17.9 (7) | 0.829 |
| 2nd | 37.7 (26) | 40.0 (12) | 35.9 (14) | 0.727 | |
| Sleepiness | 1st | 32.4 (22) | 41.4 (12) | 25.6 (10) | 0.170 |
| 2nd | 41.2 (28) | 34.5 (10) | 46.2 (18) | 0.333 |
* The percentages were calculated excluding missing values. NB: data on other adverse effects (including anaphylaxis, syncope, dyspnea, diarrhea, erythema, abdominal pain, itch, vertigo and taste alterations) with a frequency <8% are not shown here.